Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.
Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) A Good Stock To Buy?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...
Benzinga.com

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection

The approval is based on data from the phase 3 trial, which showed that Lymphir provided an overall response rate of 36%. In July 2023, the FDA rejected Citius' Biologics License Application (BLA) ...
Business Insider

Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals

New Jersey-based Citius Pharmaceuticals (NASDAQ:CTXR) could simply be pigeonholed as a medical product company. But that’s an oversimplification. Prospective CTXR stock investors deserve a much more ...
The Globe and Mail

Citius Pharmaceuticals Secures $6M in Stock Offering

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Citius Pharmaceuticals ( (CTXR)) just ...
Seeking Alpha

Citius gains as late-stage trial for Mino-Lok succeeds

Shares of Citius Pharmaceuticals (NASDAQ:CTXR) rose on Tuesday after the critical care product developer said its pivotal Phase 3 clinical trial for its Mino-Lok antibiotic lock solution succeeded.
Nasdaq

Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%

Citius Pharmaceuticals, Inc. CTXR was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than ...